Asthma quality of life during 1 year of treatment with budesonide with or without formoterol

The Formoterol and Corticosteroids Establishing Therapy (FACET) study has provided the first opportunity to examine the long-term effects of inhaled steroids and long-acting beta2-agonists on asthma-specific quality of life. The objectives of the present study were to: evaluate the effects of long-term (1 yr) formoterol and increasing doses of budesonide on asthma quality of life; 2) to determine whether initial improvements in quality of life are sustained when improvements in clinical indices persist; and 3) to evaluate the long-term relationship between changes in clinical indices and changes in quality of life. Of the 852 asthmatic adults enrolled, 470 from five countries participated in this quality of life evaluation. After a 4-week run-in on 1,600 microg budesonide, patients were randomized to either 200 microg (Bud200) or 800 microg budesonide (Bud800) in combination with either 24 microg formoterol (F) or placebo daily for 1 yr. The Asthma Quality of Life Questionnaire (AQLQ) was completed and conventional clinical indices measured at enrolment and randomization and on seven occasions during the following 12 months. During the run-in, there was an improvement in AQLQ score (changes (delta) in overall score approximately 0.50; p<0.0001). After randomization, there was a further improvement in the Bud800+F group (delta=0.21; p=0.028). One month post-randomization, improvements in all groups stabilized and were sustained throughout the 12 months in a pattern very similar to that observed for the conventional clinical indices. The correlation of individual patient changes in clinical indices and changes in AQLQ score during the 12-month randomized period were weak to moderate (maximum r=0.51). Improvements in quality of life, which were greatest in the 800 microg budesonide plus 24 microg formoterol group, were sustained throughout the 12 months in a similar manner to the clinical indices. Long-term changes in conventional clinical indices cannot be used to predict the effect of treatment on individual patient experience.

This article has been cited by other articles:

				G. H. Guyatt, C. E. Ferrans, M. Y. Halyard, D. A. Revicki, T. L. Symonds, C. G. Varricchio, A. Kotzeva, J. M. Valderas, J. L. Alonso, and Clinical Significance Consensus Meeting Group Exploration of the Value of Health-Related Quality-of-Life Information From Clinical Research and Into Clinical Practice Mayo Clin. Proc., October 1, 2007; 82(10): 1229 - 1239. [Abstract] [Full Text] [PDF]

				E. D. Bateman, J. Bousquet, M. L. Keech, W. W. Busse, T. J. H. Clark, S. E. Pedersen, and on behalf of the GOAL Investigators Group The correlation between asthma control and health status: the GOAL study Eur. Respir. J., January 1, 2007; 29(1): 56 - 62. [Abstract] [Full Text] [PDF]

				C. S. Calfee, P. P. Katz, E. H. Yelin, C. Iribarren, and M. D. Eisner The influence of perceived control of asthma on health outcomes. Chest, November 1, 2006; 130(5): 1312 - 1318. [Abstract] [Full Text] [PDF]

				O. S. Usmani, K. Ito, K. Maneechotesuwan, M. Ito, M. Johnson, P. J. Barnes, and I. M. Adcock Glucocorticoid Receptor Nuclear Translocation in Airway Cells after Inhaled Combination Therapy Am. J. Respir. Crit. Care Med., September 15, 2005; 172(6): 704 - 712. [Abstract] [Full Text] [PDF]

				L.G. Pont, T. van der Molen, P. Denig, G.T. van der Werf, and F.M. Haaijer-Ruskamp Relationship between guideline treatment and health-related quality of life in asthma Eur. Respir. J., May 1, 2004; 23(5): 718 - 722. [Abstract] [Full Text] [PDF]

				M. Romagnoli, I. Vachier, P. Tarodo de la Fuente, H. Meziane, C. Chavis, J. Bousquet, P. Godard, and P. Chanez Eosinophilic inflammation in sputum of poorly controlled asthmatics Eur. Respir. J., December 1, 2002; 20(6): 1370 - 1377. [Abstract] [Full Text] [PDF]

				E.D. Bateman, L.F. Frith, and G.L. Braunstein Achieving guideline-based asthma control: does the patient benefit? Eur. Respir. J., September 1, 2002; 20(3): 588 - 596. [Abstract] [Full Text] [PDF]

				E. F. Juniper, D. B. Price, P. A. Stampone, J. P. H. M. Creemers, S. J. M. Mol, and P. Fireman Clinically Important Improvements in Asthma-Specific Quality of Life, But No Difference in Conventional Clinical Indexes in Patients Changed From Conventional Beclomethasone Dipropionate to Approximately Half the Dose of Extrafine Beclomethasone Dipropionate* Chest, June 1, 2002; 121(6): 1824 - 1832. [Abstract] [Full Text] [PDF]

				J C Kips and R A Pauwels Low dose inhaled corticosteroids and the prevention of death from asthma Thorax, September 1, 2001; 56(90002): ii74 - 78. [Full Text] [PDF]

				A E Tattersfield, G I Town, O Johnell, C Picado, M Aubier, P Braillon, and R Karlström Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years Thorax, April 1, 2001; 56(4): 272 - 278. [Abstract] [Full Text]

				M. L. MOY, E. ISRAEL, S. T. WEISS, E. F. JUNIPER, L. DUBÉ, J. M. DRAZEN, and the NHLBI Asthma Clinical Rese Clinical Predictors of Health-related Quality of Life Depend on Asthma Severity Am. J. Respir. Crit. Care Med., March 15, 2001; 163(4): 924 - 929. [Abstract] [Full Text]